Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer...Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices.展开更多
目的：研究宫颈癌发生发展过程中组织微小RNA-21表达及高危型HPV病毒载量变化的意义。方法选取2011年3月至2015年3月收治的宫颈病变并行宫颈活检的患者150例， CINⅠ组（ n ＝39）、CINⅡ组（ n ＝37）、CINⅢ组（ n ＝34），CC组（ n ...目的：研究宫颈癌发生发展过程中组织微小RNA-21表达及高危型HPV病毒载量变化的意义。方法选取2011年3月至2015年3月收治的宫颈病变并行宫颈活检的患者150例， CINⅠ组（ n ＝39）、CINⅡ组（ n ＝37）、CINⅢ组（ n ＝34），CC组（ n ＝40），分析miR-21的表达及HR-HPV载量与宫颈癌临床病理特征的联系，miR-21的表达与HR-HPV载量的相关性，不同宫颈病变中miR-21的表达及HR-HPV载量。结果宫颈癌患者肿瘤细胞低分化者miR-21表达（6．12±0．83）低于中分化者（8．17±0．65）及高分化者（11．54±1．29）（ P ＜0．05）；肿瘤细胞直径＞4 cm者HR-HPV载量（26．53±3．12）高于＜4 cm者（23．60±2．85）（ P ＜0．05），FIGO分期Ⅰ～ⅡA者HR-HPV载量（23．86±2．34）低于ⅡB～Ⅳ者（27．59±3．12）；宫颈癌HR-HPV阳性者miR-21表达（9．75±0．83）高于HR-HPV阴性者（5．47±0．46），差异有统计学意义（ P ＜0．05）；但miR-21表达及HR-HPV载量与宫颈癌年龄、FIGO分期、病理类型、淋巴转移、脉管浸润无明显相关性（ P ＞0．05）；CINⅠ组HR-HPV阳性患者（41．03％）分别低于 CINⅡ组（67．57％）、CINⅢ组（85．29％）及CC组（92．50％），CINⅠ组mi-R21相对表达水平（6．42±0．53）低于CINⅡ组（7．26±0．61）、CINⅢ组（8．24±0．65）及CC组（9．36±0．70），差异有统计学意义（ P ＜0．05）。结论微小RNA-21表达可反应宫颈癌细胞分化程度，高危型HPV病毒载量可反应宫颈癌FIGO分期及肿瘤直径范围，微小RNA-21表达与高危型HPV病毒载量呈正相关，联合检查微小RNA-21及高危型病毒载量能够提示宫颈癌前病变、宫颈癌的发生发展。展开更多
基金the Fund of National Key R&D Program of China(Grant no.2021YFC2701205)the National Nature Science Foundation of China(Grant no.82271658)Major scientific research projects of young and middle-aged people of Fujian Provincial Health Commission(grant no.2021ZQNZD011).
文摘Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices.
文摘目的：研究宫颈癌发生发展过程中组织微小RNA-21表达及高危型HPV病毒载量变化的意义。方法选取2011年3月至2015年3月收治的宫颈病变并行宫颈活检的患者150例， CINⅠ组（ n ＝39）、CINⅡ组（ n ＝37）、CINⅢ组（ n ＝34），CC组（ n ＝40），分析miR-21的表达及HR-HPV载量与宫颈癌临床病理特征的联系，miR-21的表达与HR-HPV载量的相关性，不同宫颈病变中miR-21的表达及HR-HPV载量。结果宫颈癌患者肿瘤细胞低分化者miR-21表达（6．12±0．83）低于中分化者（8．17±0．65）及高分化者（11．54±1．29）（ P ＜0．05）；肿瘤细胞直径＞4 cm者HR-HPV载量（26．53±3．12）高于＜4 cm者（23．60±2．85）（ P ＜0．05），FIGO分期Ⅰ～ⅡA者HR-HPV载量（23．86±2．34）低于ⅡB～Ⅳ者（27．59±3．12）；宫颈癌HR-HPV阳性者miR-21表达（9．75±0．83）高于HR-HPV阴性者（5．47±0．46），差异有统计学意义（ P ＜0．05）；但miR-21表达及HR-HPV载量与宫颈癌年龄、FIGO分期、病理类型、淋巴转移、脉管浸润无明显相关性（ P ＞0．05）；CINⅠ组HR-HPV阳性患者（41．03％）分别低于 CINⅡ组（67．57％）、CINⅢ组（85．29％）及CC组（92．50％），CINⅠ组mi-R21相对表达水平（6．42±0．53）低于CINⅡ组（7．26±0．61）、CINⅢ组（8．24±0．65）及CC组（9．36±0．70），差异有统计学意义（ P ＜0．05）。结论微小RNA-21表达可反应宫颈癌细胞分化程度，高危型HPV病毒载量可反应宫颈癌FIGO分期及肿瘤直径范围，微小RNA-21表达与高危型HPV病毒载量呈正相关，联合检查微小RNA-21及高危型病毒载量能够提示宫颈癌前病变、宫颈癌的发生发展。
